ReviewDrugs2019
Dapagliflozin: A Review in Type 2 Diabetes.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05565976 (Dapagliflozin Effect in Cognitive Impairment in Stroke Trial), which is not on this map. Cited by 112 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
Who cites it
112 citing papers in PubMed, 1 synthesis or guideline pooled it, 218 citations in OpenAlex.
- Efficacy and Safety of SGLT2 Inhibitors in Pediatric Patients and Young Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Pediatric diabetes · 2024Pooled it
- The Impact of Different Oral Antidiabetic Drugs on Insulin Pump Intensive Therapy in Type 2 Diabetes Patients: A Clinical Study.Journal of diabetes research · 2026Trial
- Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up).The Journal of clinical endocrinology and metabolism · 2025Trial
- Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers, Combined with Dapagliflozin as Type 2 Diabetes Mellitus Routine Treatment: A Controlled Randomized, Double-blind Trial.Iranian journal of medical sciences · 2025Trial
- Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study.Digestive diseases and sciences · 2025Trial
- Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.The lancet. Diabetes & endocrinology · 2022Trial
- Calcium-Mechanochemistry Enabled Ketone Synthesis From Organic Iodides and Carboxylic Acids.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- POLK and KCNK17 as novel candidate genes for type 2 diabetes via stress response and ion channel regulation.Journal of endocrinological investigation · 2026Article
- Dapagliflozin attenuates cisplatin-induced nephrotoxicity in rats through modulation of ROS/NF-κB, BCL2/Bax and PINK1/Parkin signaling pathways.Scientific reports · 2026Article
- CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.Cardiovascular diabetology · 2026Article
- Article
- Targeting SLC5A2 suppresses colorectal tumour development by enhancing NK cell activity through extracellular vesicle-dependent MICA/B signalling.Clinical and translational medicine · 2026Article
- Dapagliflozin regulates chondrocyte homeostasis and protects against osteoarthritis via targets AMPKα and SGLT2.Cell death discovery · 2026Article
- The Impact of Continuous Flow Technology and Collaboration between Academia and Industry.JACS Au · 2026Review
- The application of machine learning in the evaluation of urinary tract infections incidence in patients in a Nursing and Treatment Facility.Pharmacological reports : PR · 2026Article
- Direct dapagliflozin exposure enhances respiration and membrane hyperpolarization in isolated cardiac mitochondria.Frontiers in physiology · 2026Article
- Effects of dapagliflozin on main pulmonary artery diameter in patients undergoing mitral valve replacement: a retrospective observational study.Frontiers in cardiovascular medicine · 2026Article
- Type 2 Diabetes Mellitus in Saudi Arabia: Prevalence, Risk Factors, and Management Strategies: A Review.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Pros and Cons of Early Treatment with GLP-1 Receptor Agonist and SGLT-2 Inhibitors for Youth with Type 2 Diabetes: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dapagliflozin (Forxiga
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.